“With a CGAR of 10%, the biologicals market will continue to become more attractive to investors. Consolidation will likely continue as smaller start-ups get rolled up,” said Bob Trogele, COO and EVP, AMVAC in a recent interview with AgroPages.
He also shared his views on the opportunities and challenges for biologicals; AMVAC’s biological business and global presence, product lines and special features, as well as the dynamic changes and future development trend for biologicals etc.